You are here: Industry Insights > AML

News List

Vitamin B6, leukemia's deadly addiction worldpharmanews
January 14, 2020
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and ...
Acute myeloid leukemia treatment receives FDA Orphan Drug Designation europeanpharmaceuticalreview
January 09, 2020
Orphan drug designation has been approved by the FDA for PRGN-3006 UltraCAR-T™ for patients with acute myeloid leukemia (AML).
Apollomics buys AML programme rights in Greater China pharmaceutical-technology
January 09, 2020
Apollomics has signed an exclusive collaboration and license agreement with GlycoMimetics for two acute myeloid leukaemia (AML) programmes.
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in AML americanpharmaceuticalreview
December 11, 2019
Trovagene announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.
Moleculin Announces Additional Positive Interim Results from Studies of Annamycin in AML americanpharmaceuticalreview
December 10, 2019
Moleculin Biotech announced additional positive interim safety and efficacy data from one of the Company's two ongoing open label ...
Mustang Bio’s AML Treatment Receives Orphan Drug Designation contractpharma
July 31, 2019
MB-102 (CD123 CAR T) evaluated to treat AML and BPDCN.
VANFLYTA® Receives Approval in Japan americanpharmaceuticalreview
June 20, 2019
Daiichi Sankyo announced the Ministry of Health, Labor and Welfare (MHLW) of Japan has approved VANFLYTA® (quizartinib), an oral FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML), as detecte
Biosight Receives Orphan Drug Designation for BST-236 for AML americanpharmaceuticalreview
June 06, 2019
Biosight announced the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to BST-236, an investigational novel antimetabolite, for the treatment of acute myeloid leukemia (AML).
Allo-HCT With Unrelated Donor Tied to Better Outcomes in AML drugs
June 05, 2019
Allo-HCT With Unrelated Donor Tied to Better Outcomes in AML.
FDA Approves IND Application to Initiate Relapsed or Refractory AML Clinical Trial americanpharmaceuticalreview
May 30, 2019
BioTheryX announced the U.S. Food and Drug Administration (FDA) has cleared BioTheryX's investigational new drug application (IND) for BTX-A51, an oral multi-kinase inhibitor, for the treatment of patients with ...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page